Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001584759-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-02-19 | 2026-02-17 | ELVN | Heyman Richard A. | Dir | S - Sale | $26.18 | -1,230 | 22.6K | -5% | -$32.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-17 | S | D | 1,230 | $26.18 | 22,647 | I See footnote | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. (F3) The shares are held of record by the Heyman Daigle Trust. |